Mirati Therapeutics To Present Preclinical And Clinical Data At The IASLC 16th World Conference On Lung Cancer

Company to Present Mini-Oral Presentations on:

- Non-Small Cell Lung Cancer Patient with Axl Gene Amplification in MGCD265 Phase 1/1b Study

- MGCD516 in RET and Trk Fusion Cancer Cells

Aug 21, 2015, 19:05 ET from Mirati Therapeutics, Inc.

SAN DIEGO, Aug. 21, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its two tyrosine kinase inhibitors, MGCD265 and MGCD516, at the International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer being held in Denver, CO from September 6-9, 2015.

Data from the studies will be presented during the two mini-oral sessions described below:

  • Abstract # 3611: "Evaluation of the MET/Axl Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Axl Amplification"
    Presenting author: Lynette Sholl, M.D., Brigham and Women's Hospital
    Session: Mini-Oral 30, New Kinase Targets
    Track: Treatment of Advance Diseases -NSCLC
    Time/Location: Wednesday, September 9, 2015 from 6:30 – 8:00 p.m. MT (5:30 – 7:00 p.m. PT) in Colorado Convention Center, Four Seasons Ballroom F3+F4
  • Abstract # 2756: "In Vitro and In Vivo Evaluation of the Kinase Inhibitor, MGCD516, in Trk and RET Fusion Cancer Cells"
    Presenting author: Robert Doebele, M.D., Ph.D., University of Colorado Anschutz Medical Campus, Medical Oncology/Department of Medicine
    Session: Mini-Oral 14, Pre-Clinical Therapy
    Track: Biology, Pathology and Molecular Testing
    Time/Location: Tuesday, September 8, 2015 from 10:45 a.m.12:15 p.m. MT (9:45 -11:15 a.m. PT) in Colorado Convention Center, Mile High Ballroom 2c-3c

About MGCD265
MGCD265 is a tyrosine kinase inhibitor that has demonstrated potent and selective targeting of tumors in patients with driver alterations in MET (mutations and gene amplification) and Axl (rearrangements and gene amplification) that occur in approximately 8% of patients with non-small cell lung cancer (NSCLC). MGCD265 is in the expansion phase of a Phase 1/1b dose escalation study for NSCLC patients with MET or Axl genetic alterations. Genetic alterations in these targets have been implicated as drivers of tumor growth and disease progression in NSCLC, gastroesophageal cancer and other solid tumors. Mirati retains worldwide rights to MGCD265.

About MGCD516
MGCD516 is a tyrosine kinase inhibitor that has demonstrated potent inhibition of a closely related spectrum of tyrosine kinases including RET, Trk and DDR, which are key regulators of signaling pathways that lead to cell growth, survival and tumor progression. These kinases and their key regulatory pathways are genetically altered in multiple cancer indications and act as oncogenic drivers that promote cancer development and progression in solid tumors, including non-small cell lung cancer (NSCLC). MGCD516 is in a Phase 1 dose escalation study in advanced solid tumors with an initial focus on NSCLC. Mirati retains worldwide rights to MGCD516.

About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished targeted oncology leadership team. The Mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.

Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, contain "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties. For more detailed disclosures and discussions regarding such forward looking statements, please refer to Mirati's filings with the U.S. Securities and Exchange Commission ("SEC"), including without limitation Mirati's filings on Forms 10-K, 10-Q, and 8-K. Forward looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology, or by statements that certain actions, events or results "may" or "would" be taken, occur or be achieved. Such statements include, but are not limited to, statements regarding Mirati's development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati's product candidates. Forward looking statements involve significant risks and uncertainties and are neither a prediction nor a guarantee that future events or circumstances will occur. Such risks include, but are not limited to, potential delays in development timelines or negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks described in Mirati's filings with the SEC. We are including this cautionary note to make applicable, and to take advantage of, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The information in this news release is given as of the date above and Mirati expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Company Contact:
Anne Erickson
Mirati Therapeutics Inc.
Investor Relations and Corporate Communications
858-332-3532
ericksona@mirati.com

Investor Relations and Media Relations:
Jason Spark
Canale Communications
619-849-6005
jason@canalecomm.com

 

SOURCE Mirati Therapeutics, Inc.



RELATED LINKS

http://www.mirati.com
http://www.mirati.com